Treatment options for invasive fungal infections

被引:7
作者
Ashley, Elizabeth S. Dodds
机构
[1] Duke Univ, Med Ctr, Div Infect Dis, Dept Med, Durham, NC 27710 USA
[2] Campbell Univ, Sch Pharm, Buies Creek, NC 27506 USA
来源
PHARMACOTHERAPY | 2006年 / 26卷 / 06期
关键词
amphotericin B; echinocandins; azoles; drug interactions; antifungal therapy;
D O I
10.1592/phco.26.6part2.55S
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clinicians face an increasing occurrence of invasive fungal infections. These are due not only to traditional yeast and mould species but also to rare pathogens that can be difficult to treat. The introduction of new agents has expanded the options for treating common and rare mycotic infections with antifungal efficacy at least equal, and safety far superior, to that of a once-limited choice of therapies. Patients with invasive mycoses frequently have concomitant disorders and require multidrug regimens. Clinicians must be aware of the potential for interactions among agents available for treating invasive mycoses in patients with serious underlying conditions.
引用
收藏
页码:55S / 60S
页数:6
相关论文
共 18 条
  • [1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
    Ally, R
    Schürmann, D
    Kreisel, W
    Carosi, G
    Aguirrebengoa, K
    Dupont, B
    Hodges, M
    Troke, P
    Romero, AJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
  • [2] *AST PHARM US INC, 2005, MYC MIC PACK INS
  • [3] PREVENTION OF AMPHOTERICIN-B INDUCED RENAL IMPAIRMENT - A REVIEW ON THE USE OF SODIUM SUPPLEMENTATION
    BRANCH, RA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (11) : 2389 - 2394
  • [4] ERIKSSON U, 2001, BMJ-BRIT MED J, V322, P1
  • [5] Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation
    Groll, AH
    Kolve, H
    Ehlert, K
    Paulussen, M
    Vormoor, J
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (01) : 113 - 114
  • [6] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Herbrecht, R
    Denning, DW
    Patterson, TF
    Bennett, JE
    Greene, RE
    Oestmann, JW
    Kern, WV
    Marr, KA
    Ribaud, P
    Lortholary, O
    Sylvester, R
    Rubin, RH
    Wingard, JR
    Stark, P
    Durand, C
    Caillot, D
    Thiel, E
    Chandrasekar, PH
    Hodges, MR
    Schlamm, HT
    Troke, PF
    de Pauw, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) : 408 - 415
  • [7] A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan
    Kohno, S
    Masaoka, T
    Yamaguchi, H
    Mori, T
    Urabe, A
    Ito, A
    Niki, Y
    Ikemoto, H
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (05) : 372 - 379
  • [8] Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
    Kullberg, BJ
    Sobel, JD
    Ruhnke, M
    Pappas, PG
    Viscoli, C
    Rex, JH
    Cleary, JD
    Rubinstein, E
    Church, LWP
    Brown, JM
    Schlamm, HT
    Oborska, IT
    Hilton, F
    Hodges, MR
    [J]. LANCET, 2005, 366 (9495) : 1435 - 1442
  • [9] Marr K A, 2004, Transpl Infect Dis, V6, P110, DOI 10.1111/j.1399-3062.2004.00065.x
  • [10] Cyclophosphamide metabolism is affected by azole antifungals
    Marr, KA
    Leisenring, W
    Crippa, F
    Slattery, JT
    Corey, L
    Boeckh, M
    McDonald, GB
    [J]. BLOOD, 2004, 103 (04) : 1557 - 1559